News and Events

CAR T‑cell therapy is a leading immunotherapeutic option for relapsed or treatment‑resistant B‑cell cancers, using genetically modified T‑cells to recognize and eliminate malignant B‑cells. Eurofins Viracor’s ExPeCT™ CAR T‑Cell Persistence Assays provide clinicians with a validated, quantitative tool to monitor CAR T‑cell expansion and persistence, supporting informed treatment decisions and long‑term remission assessment.